Qritive, a Singapore-based healthcare AI startup, raised $7.5M in funding.
The round was led by MassMutual Ventures, with participation from SEEDS Capital and Exfinity Venture Partners.
The company intends to use the funds to drive geographical expansion, expand product portfolio and support regulatory clearances.
Founded in 2017 by Dr. Aneesh Sathe and Dr. Kaveh Taghipour, Qritive is an Artificial Intelligence (AI) solution developer that is advancing digital pathology for cancer diagnosis, enhancing imaging accuracy and improving health outcomes with the assistance of AI based solutions. Using artificial intelligence, the company’s solutions provide accurate interpretations of pathology whole slide images scans within seconds, reducing time to treatment, increasing accuracy for cancer care. The technology helps accelerate cancer diagnosis across multiple cancer types including colon, prostate, lymph node, breast and includes a robust set of tools for immunohistochemistry.
Qritive’s solutions are CE certified and also approved by Singapore Health Sciences Authority (HSA).
The company today has U.S. operations in San Diego and India operations in Pune.
FinSMEs
09/01/2023